Detalhe da pesquisa
1.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363867
2.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 25(6): 744-759, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38821083
3.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108374
4.
Dimerization and Crowding in the Binding of Interleukin 8 to Dendritic Glycosaminoglycans as Artificial Proteoglycans.
Chemistry
; 30(13): e202302758, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38010268
5.
Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma.
Ann Hematol
; 102(12): 3445-3455, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37566280
6.
Human Cord Blood B Cells Differ from the Adult Counterpart by Conserved Ig Repertoires and Accelerated Response Dynamics.
J Immunol
; 206(12): 2839-2851, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34117106
7.
T-cell prolymphocytic leukemia is associated with deregulation of oncogenic microRNAs on transcriptional and epigenetic level.
Genes Chromosomes Cancer
; 61(7): 432-436, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35218115
8.
Sulfation Pattern Dependent Iron(III) Mediated Interleukin-8 Glycan Binding.
Chembiochem
; 23(3): e202100552, 2022 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34851004
9.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol
; 108(1): 73-83, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496096
10.
Insights into structure, affinity, specificity, and function of GAG-protein interactions through the chemoenzymatic preparation of defined sulfated oligohyaluronans.
Biol Chem
; 402(11): 1375-1384, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34291624
11.
Structural insights into the modulation of PDGF/PDGFR-ß complexation by hyaluronan derivatives.
Biol Chem
; 402(11): 1441-1452, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34280958
12.
Identification of intracellular glycosaminoglycan-interacting proteins by affinity purification mass spectrometry.
Biol Chem
; 402(11): 1427-1440, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34472763
13.
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica
; 106(2): 543-554, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107341
14.
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.
Eur J Haematol
; 107(4): 449-457, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34185342
15.
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia.
Genes Chromosomes Cancer
; 59(4): 261-267, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31677197
16.
Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus-infected individuals.
Blood
; 131(5): 546-557, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29242186
17.
Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
Eur J Haematol
; 105(6): 786-796, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32875608
18.
Socioeconomic Position is Positively Associated with Monoclonal Gammopathy of Undetermined Significance in a Population-based Cohort Study.
Ann Hematol
; 98(12): 2761-2767, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31691002
19.
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Ann Hematol
; 98(4): 897-907, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30610279
20.
Light chain monoclonal gammopathy of undetermined significance is characterized by a high disappearance rate and low risk of progression on longitudinal analysis.
Ann Hematol
; 97(8): 1463-1469, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29629484